The French-American company develops the Maestro system to support surgeons in soft tissue surgical procedures. The platform acts as a robotic surgical assistant to augment the precision and control of laparoscopic surgery.
Moon Surgical’s small, adaptable system can integrate into existing clinical workflows. It features capabilities that bolster operating room efficiency and allow for alternative labor models.
The company earmarked its latest fundraising to support the continued development and planned commercialization for Maestro. Moon Surgical received FDA 510(k) clearance for Maestro in December 2022, followed by CE mark last month. In June 2022, Moon Surgical completed a $31.3 million Series A fundraising.
Sofinnova Partners co-led …